Xofluza Approved for Postexposure Prevention of Flu
Influenza infection and symptoms occurred in 1 and 13 percent of those receiving Xofluza and placebo, respectively
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.